Screening & Prevention — MCQs
On this page
A 56-year-old man with schizophrenia maintained on olanzapine presents for cardiovascular risk assessment. He has gained 18 kg over 2 years, current BMI 34 kg/m². He smokes 15 cigarettes daily. Blood tests show HbA1c 46 mmol/mol, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L. BP 142/88 mmHg. QRISK3 is 18.5%. What is the most important initial lifestyle intervention for this patient?
A 33-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology. She is anxious about cancer risk and asks what this means. Her previous screening 3 years ago was hrHPV negative. What is the most appropriate management according to current NHS cervical screening protocols?
A 72-year-old man with hypertension and hyperlipidaemia attends for medication review. His QRISK3 score is 28%. He takes ramipril 10mg daily and atorvastatin 80mg at night. He asks what else he can do to reduce his cardiovascular risk. Which dietary modification has the strongest evidence for secondary cardiovascular disease prevention?
A 47-year-old woman attends requesting early breast screening. Her sister was recently diagnosed with breast cancer at age 51, and her maternal grandmother had ovarian cancer at age 68. She is otherwise well with no breast symptoms. Using NICE guidelines for familial breast cancer, what is the most appropriate initial management?
A 53-year-old woman with a BMI of 38 kg/m² and type 2 diabetes attends for weight management review. Despite dietary modification and increased activity over 6 months, she has lost only 2 kg. Her HbA1c is 64 mmol/mol on metformin 1g BD. She asks about weight loss medications. What is the most appropriate pharmacological option to consider first?
A 66-year-old woman with a 45 pack-year smoking history attends after successfully quitting smoking 2 months ago using varenicline. She remains abstinent and asks about lung cancer screening, having read about it online. She has mild COPD (FEV1/FVC 0.68, FEV1 78% predicted) but no respiratory symptoms currently. What is the most appropriate advice?
A 29-year-old woman attends at 8 weeks gestation in her first pregnancy. She had a previous early miscarriage at age 26. She is of white British ethnicity with no family history of haemoglobinopathy. Her booking blood tests show: Hb 108 g/L, MCV 72 fL. Iron studies show ferritin 8 mcg/L. What is the most appropriate next step regarding antenatal screening?
A 40-year-old man attends for an NHS Health Check. He works as a taxi driver, sits for most of the day, and does no regular exercise. His BMI is 27 kg/m², blood pressure 128/82 mmHg, and QRISK3 score 8%. He is keen to reduce his cardiovascular risk. What evidence-based lifestyle intervention has the strongest evidence for cardiovascular disease prevention in this patient?
A 58-year-old woman attends discussing her recent NHS breast screening result which shows scattered fibroglandular densities and is otherwise normal (M1). She has a strong family history: her mother was diagnosed with breast cancer at age 42, and her maternal aunt at age 38. She asks about additional screening. What is the most appropriate management?
A 25-year-old woman receives her first cervical screening invitation. She had the HPV vaccination at age 13 (full 2-dose schedule). She has had one sexual partner and asks if she still needs screening given her vaccination history. What is the most appropriate advice?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 131: A 56-year-old man with schizophrenia maintained on olanzapine presents for cardiovascular risk assessment. He has gained 18 kg over 2 years, current BMI 34 kg/m². He smokes 15 cigarettes daily. Blood tests show HbA1c 46 mmol/mol, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L. BP 142/88 mmHg. QRISK3 is 18.5%. What is the most important initial lifestyle intervention for this patient?
- A. Referral to tier 3 weight management service for intensive behavioral intervention
- B. Smoking cessation with combination nicotine replacement therapy and varenicline
- C. Supervised physical activity programme addressing both weight and mental health
- D. Therapeutic lifestyle change diet focused on reducing LDL cholesterol
- E. Smoking cessation alongside dietary advice to prevent further weight gain (Correct Answer)
Explanation: ***Smoking cessation alongside dietary advice to prevent further weight gain*** - **Smoking** is the single most modifiable risk factor for cardiovascular disease (CVD) in patients with severe mental illness, making **cessation** the highest clinical priority for immediate risk reduction. - Since **smoking cessation** frequently leads to **weight gain**, combining it with **dietary advice** is crucial for patients already experiencing **metabolic disturbance** and weight gain from antipsychotics like **olanzapine**. *Referral to tier 3 weight management service for intensive behavioral intervention* - While the patient has a **BMI of 34 kg/m²**, intensive weight management services are typically secondary to addressing the most significant and immediate modifiable risk factor, which is **smoking**. - Tier 3 services are usually reserved after less intensive interventions have been attempted or for more complex cases, making it not the *most important initial* lifestyle intervention in this context. *Smoking cessation with combination nicotine replacement therapy and varenicline* - **Smoking cessation** is vital, but this option describes a **pharmacological intervention**, not solely a lifestyle one, and specifies a particular combination of drugs that may not be the initial step without further assessment. - This option, while crucial, does not explicitly include the vital component of **dietary advice** to manage the **olanzapine-induced weight gain** and metabolic risks, which is a key consideration for this patient. *Supervised physical activity programme addressing both weight and mental health* - **Physical activity** is highly beneficial for both **weight management** and **mental health** in patients with **schizophrenia** and is an important lifestyle change. - However, its impact on reducing immediate cardiovascular risk, while significant long-term, is not as rapid or substantial as **smoking cessation** in a patient with such a high **QRISK3 score**. *Therapeutic lifestyle change diet focused on reducing LDL cholesterol* - While the patient has **hyperlipidaemia** and a high **QRISK3 score**, a diet solely focused on **LDL cholesterol reduction** does not address the broader metabolic risks (weight gain, pre-diabetes) from **olanzapine**. - More importantly, focusing on a specific dietary component, while beneficial, does not supersede the paramount importance of **smoking cessation** as the *most important initial* lifestyle intervention for overall CVD risk reduction.
Question 132: A 33-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology. She is anxious about cancer risk and asks what this means. Her previous screening 3 years ago was hrHPV negative. What is the most appropriate management according to current NHS cervical screening protocols?
- A. Refer for immediate colposcopy
- B. Reassure and invite for routine screening in 3 years
- C. Arrange HPV genotyping for types 16 and 18
- D. Repeat hrHPV test in 12 months (Correct Answer)
- E. Repeat hrHPV test and cytology in 3 months
Explanation: ***Repeat hrHPV test in 12 months***- According to **NHS cervical screening protocols**, when **hrHPV is detected** but **cytology is negative**, the patient must be recalled in 12 months to check for viral persistence.- Most **HPV infections are transient** and clear spontaneously; repeating the test at 12 months allows time for clearance while monitoring those at higher risk of developing persistent infection.*Refer for immediate colposcopy*- **Colposcopy** is indicated if hrHPV is positive and **cytology is abnormal** (reflex cytology shows dyskaryosis) or after **persistent hrHPV** results over 24 months.- Immediate referral for normal cytology would lead to **over-investigation** and unnecessary anxiety for a condition that often resolves without intervention.*Reassure and invite for routine screening in 3 years*- Reassurance is important, but returning to **routine 3-year recall** is unsafe because the presence of hrHPV requires closer monitoring than the general population.- Patients with **hrHPV positive** results remain in the "surveillance" pathway until they are either HPV negative or referred for further diagnostic workup.*Arrange HPV genotyping for types 16 and 18*- While **HPV 16 and 18** are the highest-risk strains, specific genotyping is not currently used as a standalone triage step in the standard **NHS screening algorithm**.- The management pathway is determined by the presence of any **high-risk HPV** subtype combined with reflex **cytology findings**.*Repeat hrHPV test and cytology in 3 months*- A **3-month interval** is too short to allow for natural viral clearance and is not a recognized interval in the screening protocol.- Short-interval repeats are typically reserved for **inadequate samples**, whereas a 12-month wait is the standard for monitoring **cytology-negative/HPV-positive** cases.
Question 133: A 72-year-old man with hypertension and hyperlipidaemia attends for medication review. His QRISK3 score is 28%. He takes ramipril 10mg daily and atorvastatin 80mg at night. He asks what else he can do to reduce his cardiovascular risk. Which dietary modification has the strongest evidence for secondary cardiovascular disease prevention?
- A. Mediterranean-style diet rich in olive oil, nuts, fish, and vegetables (Correct Answer)
- B. Strict low-carbohydrate ketogenic diet (<50g carbohydrates daily)
- C. Vegetarian diet eliminating all meat and fish
- D. Low-fat diet with <20% calories from fat
- E. Intermittent fasting with 16:8 time-restricted eating
Explanation: ***Mediterranean-style diet rich in olive oil, nuts, fish, and vegetables***- The **Mediterranean diet** has the strongest evidence base for cardiovascular risk reduction, supported by landmark studies like the **PREDIMED trial**, which showed a ~30% reduction in major cardiovascular events.- It emphasizes **monounsaturated fats** (olive oil), **omega-3 fatty acids** (fish/nuts), and **antioxidants** from plant sources, which collectively improve endothelial function and reduce inflammation.*Strict low-carbohydrate ketogenic diet (<50g carbohydrates daily)*- While effective for rapid **weight loss** and glycemic control, there is a lack of long-term evidence regarding its impact on **cardiovascular mortality**.- High intake of **saturated fats** often associated with this diet may adversely affect **LDL-cholesterol** levels in some individuals.*Vegetarian diet eliminating all meat and fish*- Although associated with lower **ischaemic heart disease** risk compared to meat-eaters, the evidence is less robust than that for the Mediterranean pattern, which includes beneficial **oily fish**.- Strict vegetarianism requires careful management to avoid deficiencies (like **Vitamin B12**) and does not inherently guarantee heart-healthy fat choices.*Low-fat diet with <20% calories from fat*- Historically recommended, but large-scale trials have shown that replacing fats with **refined carbohydrates** does not reduce cardiovascular risk.- Modern guidelines favor the **quality of fat** (unsaturated vs. saturated) over a simple reduction in total fat quantity.*Intermittent fasting with 16:8 time-restricted eating*- This approach can help with **weight management** and insulin sensitivity, but it currently lacks large-scale, long-term **cardiovascular outcome trials**.- It is generally considered a tool for **caloric restriction** rather than a specific cardioprotective nutritional intervention.
Question 134: A 47-year-old woman attends requesting early breast screening. Her sister was recently diagnosed with breast cancer at age 51, and her maternal grandmother had ovarian cancer at age 68. She is otherwise well with no breast symptoms. Using NICE guidelines for familial breast cancer, what is the most appropriate initial management?
- A. Reassure that she has average population risk and advise routine NHS screening from age 50 (Correct Answer)
- B. Refer to breast surgery for immediate mammography
- C. Refer to clinical genetics for formal risk assessment
- D. Arrange mammography now and annually until age 50
- E. Use primary care risk assessment tools and arrange mammography if lifetime risk >17%
Explanation: ***Reassure that she has average population risk and advise routine NHS screening from age 50***- Per **NICE guidelines (CG164)**, this patient has only one first-degree relative diagnosed over age 40 and one second-degree relative with ovarian cancer over age 60, which falls into the **near-population risk** category.- Specialist referral or early screening is not indicated as she does not meet the threshold of having a first-degree relative diagnosed **under age 40** or multiple relatives on the same side of the family diagnosed at young ages.*Refer to breast surgery for immediate mammography*- Immediate referral to **breast surgery** is indicated for patients with **red-flag symptoms** (e.g., lumps, skin changes), but this patient is asymptomatic.- Mammography is not recommended for **average-risk** women outside of the routine **NHS Breast Screening Programme** starting at age 50.*Refer to clinical genetics for formal risk assessment*- **Clinical genetics** referral is reserved for patients meeting "moderate" or "high risk" criteria, such as those with a calculated **lifetime risk >17%** or specific family clusters.- This patient's family history of a sister at age 51 and grandmother at age 68 does not reach the minimum **referral thresholds** for specialist genetic assessment.*Arrange mammography now and annually until age 50*- **Annual mammograms** for women aged 40–49 are only offered to those categorized as having a **moderate risk** (e.g., one first-degree relative diagnosed <40).- Providing additional screening to **average-risk** patients increases the risk of **false positives** and unnecessary anxiety without proven clinical benefit.*Use primary care risk assessment tools and arrange mammography if lifetime risk >17%*- While **primary care tools** (like IBIS or BOADICEA) can be used, this patient's history is clearly below the threshold where formal **lifetime risk calculation** is required to justify early screening.- A **17% lifetime risk** (moderate risk) requires more significant familial clustering than a single relative diagnosed post-menopause and an elderly relative with ovarian cancer.
Question 135: A 53-year-old woman with a BMI of 38 kg/m² and type 2 diabetes attends for weight management review. Despite dietary modification and increased activity over 6 months, she has lost only 2 kg. Her HbA1c is 64 mmol/mol on metformin 1g BD. She asks about weight loss medications. What is the most appropriate pharmacological option to consider first?
- A. Orlistat 120 mg three times daily with meals
- B. GLP-1 receptor agonist (e.g., semaglutide) (Correct Answer)
- C. Phentermine as short-term appetite suppressant
- D. Naltrexone-bupropion combination therapy
- E. Increase metformin to maximum dose for weight benefits
Explanation: ***GLP-1 receptor agonist (e.g., semaglutide)*** - For patients with **Type 2 Diabetes** and **obesity (BMI 38 kg/m²)**, **GLP-1 receptor agonists** are the most appropriate first-line pharmacological option as they provide significant **weight loss** and improved **glycaemic control (HbA1c 64 mmol/mol)**. - These agents work by enhancing satiety, slowing gastric emptying, and stimulating glucose-dependent insulin secretion, making them highly effective in this clinical scenario. *Orlistat 120 mg three times daily with meals* - **Orlistat** inhibits **gastric and pancreatic lipases**, reducing dietary fat absorption and leading to modest weight loss, but it lacks the robust **glycaemic benefits** of GLP-1 agonists. - Its efficacy is often limited by common gastrointestinal side effects such as **steatorrhea** and flatulence, which can affect adherence. *Phentermine as short-term appetite suppressant* - **Phentermine** is a sympathomimetic appetite suppressant generally intended for **short-term use** (typically <12 weeks) due to potential for **cardiovascular side effects** (e.g., hypertension, tachycardia) and risk of dependence. - It is not suitable for long-term weight management in a patient with **Type 2 Diabetes** and does not provide comprehensive **glycaemic control** benefits. *Naltrexone-bupropion combination therapy* - This combination targets central pathways involved in **appetite and reward**, promoting weight loss, but it is often considered a second-line agent compared to GLP-1 agonists in patients with **Type 2 Diabetes**. - While effective, it typically does not offer the same magnitude of **HbA1c reduction** and established guideline preference as GLP-1 receptor agonists in this specific patient population. *Increase metformin to maximum dose for weight benefits* - The patient is already on **metformin 1g BD**, and while metformin is weight-neutral or can cause mild weight loss, further increasing the dose is unlikely to achieve clinically significant **weight reduction** for a patient with a BMI of 38 kg/m². - Her persistent **HbA1c of 64 mmol/mol** indicates a need for a more potent glucose-lowering and weight-reducing agent beyond maximum metformin monotherapy.
Question 136: A 66-year-old woman with a 45 pack-year smoking history attends after successfully quitting smoking 2 months ago using varenicline. She remains abstinent and asks about lung cancer screening, having read about it online. She has mild COPD (FEV1/FVC 0.68, FEV1 78% predicted) but no respiratory symptoms currently. What is the most appropriate advice?
- A. She should have annual chest X-rays through her GP
- B. She should have a one-off CT chest now she has quit smoking
- C. She is not eligible as she has already quit smoking
- D. She is eligible for the NHS targeted lung health check programme (Correct Answer)
- E. Lung cancer screening is not currently available through NHS
Explanation: ***She is eligible for the NHS targeted lung health check programme*** - The **NHS Targeted Lung Health Check (TLHC)** program is aimed at individuals aged **55 to 74** who have ever smoked, including those who have recently quit. - Her age (66) and **45 pack-year smoking history** qualify her as high-risk, making her eligible for assessment and potential **low-dose CT (LDCT)** screening. *She should have annual chest X-rays through her GP* - **Chest X-rays** are not recommended for lung cancer screening due to their low **sensitivity** in detecting early-stage lung nodules. - Studies have shown that **annual chest X-rays** do not significantly reduce **lung cancer mortality**, unlike **low-dose CT** screening. *She should have a one-off CT chest now she has quit smoking* - Lung cancer screening through programs like TLHC involves a **systematic risk assessment** rather than an immediate, self-requested "one-off" CT scan. - If deemed high risk, the screening protocol typically involves **serial low-dose CT scans** at specific intervals, not just a single baseline scan. *She is not eligible as she has already quit smoking* - Eligibility criteria for lung cancer screening explicitly include **former smokers**, often those who have quit within the last **15 years**, due to their continued elevated risk. - Quitting only **2 months ago** means her cumulative smoking risk remains significant, making her a prime candidate for screening. *Lung cancer screening is not currently available through NHS* - This statement is incorrect; the **NHS Targeted Lung Health Check** program has been actively rolling out across England since 2019. - The program aims to become a **national screening programme** for lung cancer, demonstrating its current availability and expansion.
Question 137: A 29-year-old woman attends at 8 weeks gestation in her first pregnancy. She had a previous early miscarriage at age 26. She is of white British ethnicity with no family history of haemoglobinopathy. Her booking blood tests show: Hb 108 g/L, MCV 72 fL. Iron studies show ferritin 8 mcg/L. What is the most appropriate next step regarding antenatal screening?
- A. Start iron supplementation and proceed with routine antenatal screening only
- B. Offer haemoglobinopathy screening with Hb electrophoresis before starting iron (Correct Answer)
- C. Check serum B12 and folate before further action
- D. Arrange immediate partner screening for haemoglobinopathy
- E. Start iron supplementation and arrange Hb electrophoresis simultaneously
Explanation: ***Offer haemoglobinopathy screening with Hb electrophoresis before starting iron***- The patient presents with **microcytic anaemia** (MCV 72 fL) and low **ferritin** (8 mcg/L), which necessitates investigation for underlying **haemoglobinopathies** in pregnancy, regardless of ethnicity. - It is crucial to perform **Hb electrophoresis** *before* starting iron supplementation because severe iron deficiency can cause a **false decrease in HbA2 levels**, which could mask a diagnosis of **beta-thalassaemia trait**. *Start iron supplementation and proceed with routine antenatal screening only*- Although **iron deficiency** is present, starting iron without prior **haemoglobinopathy screening** in a patient with microcytosis can obscure or delay the diagnosis of an underlying genetic condition.- Routine antenatal screening is insufficient when **microcytic anaemia** has already been identified; specific diagnostic tests like Hb electrophoresis are required. *Check serum B12 and folate before further action*- Deficiencies in **vitamin B12** and **folate** typically lead to **macrocytic anaemia** (high MCV), which is not consistent with this patient's **low MCV** of 72 fL.- These tests would not address the primary concern of identifying a potential **haemoglobinopathy**, which is indicated by the microcytic picture. *Arrange immediate partner screening for haemoglobinopathy*- Partner screening is only indicated and useful if the mother is first confirmed to be a **carrier** of a clinically significant **haemoglobinopathy** (e.g., thalassaemia or sickle cell trait).- The initial and most appropriate step is to establish the mother's **carrier status** definitively through her own diagnostic tests. *Start iron supplementation and arrange Hb electrophoresis simultaneously*- While it may seem efficient, commencing **iron supplementation** can quickly alter erythropoiesis and haemoglobin synthesis, potentially impacting the accurate interpretation of the **Hb electrophoresis** results.- Current guidelines emphasize obtaining a baseline **Hb electrophoresis** result prior to initiating **iron therapy** to avoid misdiagnosis, especially regarding **HbA2 levels**.
Question 138: A 40-year-old man attends for an NHS Health Check. He works as a taxi driver, sits for most of the day, and does no regular exercise. His BMI is 27 kg/m², blood pressure 128/82 mmHg, and QRISK3 score 8%. He is keen to reduce his cardiovascular risk. What evidence-based lifestyle intervention has the strongest evidence for cardiovascular disease prevention in this patient?
- A. Reducing dietary saturated fat intake to <10% total energy
- B. Achieving 150 minutes of moderate-intensity aerobic activity per week (Correct Answer)
- C. Weight loss of 5-10% body weight through calorie restriction
- D. Increasing daily fibre intake to 30 grams per day
- E. Reducing alcohol consumption to within recommended limits
Explanation: ***Achieving 150 minutes of moderate-intensity aerobic activity per week*** - Regular **physical activity** has the most robust evidence for primary prevention of cardiovascular disease (CVD), showing a significant reduction in risk. - For a **sedentary patient** like a taxi driver, physical activity directly improves metabolic health, **blood pressure**, and lipid profiles, independent of other factors. *Reducing dietary saturated fat intake to <10% total energy* - While **reducing saturated fats** and replacing them with polyunsaturated fats lowers lipids, its impact on overall CVD mortality is generally smaller than that of consistent physical activity. - This intervention is a standard part of a healthy diet but is rarely as effective on its own as a multi-modal exercise regimen for primary prevention. *Weight loss of 5-10% body weight through calorie restriction* - Although this patient has a **BMI of 27 kg/m²** (overweight), calorie restriction alone is less effective for long-term CVD risk reduction than increasing **cardiorespiratory fitness**. - Weight loss improves individual risk factors, but exercise provides unique **cardioprotective benefits** and metabolic improvements that diet-induced weight loss alone may lack. *Increasing daily fibre intake to 30 grams per day* - High **fibre intake** is associated with lower cholesterol and improved bowel health, but the evidence for isolated fibre supplementation as the strongest standalone intervention is weaker than for regular exercise. - It serves as a supportive measure in comprehensive **dietary modifications** rather than the primary lifestyle intervention with the strongest evidence base for CVD prevention. *Reducing alcohol consumption to within recommended limits* - While **excessive alcohol** consumption increases CVD risk and blood pressure, reducing consumption does not offer the same comprehensive and robust protection as consistent **aerobic activity**. - There is no indication in the patient's presentation that he is currently exceeding the **recommended alcohol limits**, making it less likely to be the *strongest* evidence-based intervention for *this* patient.
Question 139: A 58-year-old woman attends discussing her recent NHS breast screening result which shows scattered fibroglandular densities and is otherwise normal (M1). She has a strong family history: her mother was diagnosed with breast cancer at age 42, and her maternal aunt at age 38. She asks about additional screening. What is the most appropriate management?
- A. Continue with routine NHS breast screening every 3 years
- B. Arrange annual mammography through standard NHS services
- C. Refer to clinical genetics for risk assessment and consideration of enhanced surveillance (Correct Answer)
- D. Arrange MRI breast screening immediately
- E. Recommend bilateral prophylactic mastectomy
Explanation: ***Refer to clinical genetics for risk assessment and consideration of enhanced surveillance*** - This patient has a **significant family history** (mother diagnosed at 42, maternal aunt at 38), indicating a potential **moderate to high lifetime risk** of breast cancer. - Referral to **clinical genetics** allows for a formal **risk assessment**, genetic counseling, and potential **genetic testing** (e.g., for BRCA mutations) to guide appropriate **enhanced surveillance** strategies. *Continue with routine NHS breast screening every 3 years* - Routine screening is appropriate for women at **average risk**, but this patient's strong family history places her at a potentially **higher risk**. - This option would fail to identify and manage her elevated risk, potentially delaying the detection of breast cancer if it were to occur. *Arrange annual mammography through standard NHS services* - While **annual mammography** is a form of enhanced surveillance, it should be initiated only after a formal **risk assessment** by clinical genetics or a specialist breast unit. - Ordering it directly without a comprehensive risk evaluation is not the appropriate first step in managing her family history. *Arrange MRI breast screening immediately* - **Breast MRI** is reserved for women identified as being at **very high risk** (e.g., confirmed BRCA carriers or lifetime risk >30%) after a detailed risk assessment. - Prescribing it immediately without a formal risk stratification is premature and not evidence-based for initial management of family history. *Recommend bilateral prophylactic mastectomy* - **Bilateral prophylactic mastectomy** is a drastic measure considered only for women at **extremely high risk** (e.g., confirmed BRCA1/2 mutation) after extensive counseling and shared decision-making. - Recommending such surgery at this stage, before any formal risk assessment or genetic testing, is highly inappropriate.
Question 140: A 25-year-old woman receives her first cervical screening invitation. She had the HPV vaccination at age 13 (full 2-dose schedule). She has had one sexual partner and asks if she still needs screening given her vaccination history. What is the most appropriate advice?
- A. She does not require screening as she is fully vaccinated against HPV
- B. She should attend for screening as vaccination does not provide complete protection (Correct Answer)
- C. She should delay screening until age 30 due to her vaccination status
- D. She only requires screening if she develops symptoms
- E. She requires screening only if she has multiple sexual partners
Explanation: ***She should attend for screening as vaccination does not provide complete protection*** - Although the **HPV vaccine** covers major high-risk types like 16 and 18, it does not provide immunity against **all oncogenic HPV types** that can lead to cervical cancer. - Regular **cervical screening** remains the standard of care for all eligible women starting at age **25**, regardless of their vaccination or sexual history, to detect pre-cancerous changes. *She does not require screening as she is fully vaccinated against HPV* - Vaccination is **prophylactic** and reduces risk significantly but does not eliminate the possibility of infection from non-covered **high-risk HPV** strains. - Guidelines mandate participation in the **screening programme** to detect pre-cancerous changes that the vaccine might not have prevented. *She should delay screening until age 30 due to her vaccination status* - Current protocols state that the first invitation for screening should occur at age **25** for all women, irrespective of whether they received the vaccine at a younger age. - Delaying screening would increase the risk of missing early **cytological abnormalities** or persistent infections that could progress to malignancy. *She only requires screening if she develops symptoms* - Cervical screening is a **preventative tool** designed to detect asymptomatic abnormalities; waiting for symptoms like **intermenstrual bleeding** indicates a possible advanced stage. - Screening is highly effective precisely because it identifies **pre-invasive lesions** before they become symptomatic or cancerous. *She requires screening only if she has multiple sexual partners* - While having **multiple sexual partners** increases the risk of HPV exposure, any level of sexual activity warrants inclusion in the screening programme. - HPV is extremely common, and even a single partner can transmit **high-risk strains**, making universal screening at age **25** essential for safety.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free